Related Experiment Videos
[Myelodysplastic syndromes in the aged]
M Kawakami1, H Tsutsumi, M Hirai
1Department of Hematology, Tokyo Metropolitan Geriatric Hospital.
Abstract:
Seventy-five cases of myelodysplastic syndromes (MDS) in the aged (over 60 years) were analysed for hematological findings, immunological parameters and response to treatment in respect to prognostic significance. They were diagnosed according to the FAB classification, but patients with hypoplastic marrow were included if myelodysplasia was evident. Thirty-four percent of patients with primary acquired refractory anemia (PARA) or primary acquired sideroblastic anemia (PASA), and 36% of patients with RA with excess of blasts (RAEB) had hypoplastic bone marrow. The positive rates of antinuclear antibody in PARA or PASA, and of rheumatoid factor in PARA or PASA and in RAEB were higher than those in normal aged controls. Cellularity of bone marrow was inversely related to the length of survival. Among the patients with PARA or PASA, survival time was significantly longer in the group of hypoplastic bone marrow than in the group of hyper- or normo-plastic bone marrow, and in the group of good responder to treatment than in the group of poor responder and nontreated patients.
Insights
This study on myelodysplastic syndromes (MDS) in older adults found that hypoplastic bone marrow and good treatment response correlate with longer survival. Immunological markers also showed differences in MDS patients compared to controls.
Area of Science:
- Hematology
- Immunology
- Geriatrics
Context:
- Myelodysplastic syndromes (MDS) are a group of clonal hematopoietic stem cell disorders.
- MDS predominantly affects the elderly population.
- Accurate prognostic indicators are crucial for managing MDS in aged patients.
Purpose:
- To analyze hematological findings, immunological parameters, and treatment response in elderly MDS patients.
- To determine the prognostic significance of these factors for survival.
- To investigate the role of bone marrow cellularity and specific antibodies in MDS prognosis.
Summary:
- A study of 75 elderly patients diagnosed with MDS (including hypoplastic marrow cases) revealed prognostic factors.
- Higher rates of antinuclear and rheumatoid factors were observed in MDS patients versus controls.
- Bone marrow cellularity inversely correlated with survival; hypoplastic marrow and good treatment response predicted longer survival in specific MDS subtypes (PARA/PASA).
Impact:
- Identifies key prognostic indicators for myelodysplastic syndromes in the elderly.
- Highlights the importance of bone marrow cellularity and treatment response in predicting survival outcomes.
- Provides insights into the immunological characteristics of MDS in older individuals, aiding clinical management.